ADT add-ons helpful in metastatic prostate cancer

Reuters Health - 20/01/2021 - Addition of abiraterone acetate or apalutamide to androgen-deprivation therapy (ADT) in men with metastatic castration-sensitive prostate cancer (mCSPC) are among approaches offering the biggest benefit with the least risk, according to a network meta-analysis. "Among systemic mCSPC treatments currently approved by the U.S. Food and Drug Administration and recommended by clinical guidelines, abiraterone acetate was associated with the most considerable overall survival benefit with relatively low risks of serious adverse events," Dr. Lin Wang of Johns Hopkins University Bloomberg School of Public Health, in Baltimore, Maryland, told Reuters Health by email. In a paper in JAMA Oncology, Dr. Wang and colleagues note that mCSPC is associated with high mortality, with a five-year survival rate of only 30%. A number of treatments added to ADT can delay disease progression. However, the authors say that the lack of head-to-head trials ...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 20 January, 20211 February, 2021